Veracyte
Highly Engaged Employees
Highly Engaged EmployeesHealthcare Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
6000 Shoreline Ct Ste 300, South San Fra...Phone Number
(650) 243-6300Website
www.veracyte.comRevenue
$561.9 MillionStock Symbol
VCYTIndustry
ZI Rank: 12
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
14
15
17
12
12
12
About Veracyte
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.Explore more
Veracyte Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Veracyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Veracyte, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Veracyte has new funding data
Check if Veracyte has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Veracyte
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Veracyte launches new products
Click to see if Veracyte had a recent Job posting/layoffs
Check out if Veracyte is spiking on competitors!
Earning: See what the market has to say on Veracyte recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Veracyte
Compare insights from companies similar to Veracyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Veracyte is experiencing low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Veracyte is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Veracyte.
Veracyte financials insights
Gather financial insights about Veracyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series B
$28M
2013
Series C
$28M
Stock Offering
$58M
2015
Share Placement
$40M
2016
Debt
$45M
Stock Offering
$31.9M
2018
Stock Offering
$55.1M
2019
Stock Offering
$137.9M
2020
Stock Offering
$194M
Veracyte Tech Stack
A closer look at the technologies used by Veracyte
See more technologies
Most Recent Scoops
Person-Based
Spending/Investment, Product Launch
Person-Based
Medical Research
Project
Veracyte has reported that OPTIMA trial data, presented at ASCO, demonstrated that two out of three women receiving chemotherapy do not need it and that omitting chemotherapy does not impact outcomes, marking the first trial to examine patients with three or more nodes in the premenopausal population.
Clinical Operations
Earnings
Veracyte has reported Decipher revenue growth of 20% for Q2, while volume growth came in at 17%, the first time below 20% in approximately 12 to 13 quarters, with the volume shortfall of approximately 700 tests concentrated in the low-risk setting.
Earnings, Finance
Project
Medical Research
Veracyte News & Media
Veracyte Acquires Convergent Genomics for $150M, Adds Urine-Based Cancer Test
The deal adds Convergent's UroAmp urinary tumor DNA platform for non-muscle invasive bladder cancer.Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Veracyte, Inc. (VCYT) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 7:00 AM EDTCompany ParticipantsMarc Stapley - CEO &...Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journeyVeracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Veracyte
Sign Up For FreeTo access detailed company insights
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.... Read More
